Question · asked by 1 review

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo: Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of

Population
adults with alopecia areata
Intervention
Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib)
Comparison
placebo
Outcome
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of

Summary of findings table ‐ Topical small molecule inhibitors… showed no clear difference in short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (low certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
Summary of findings table ‐ Topical small molecule inhibitors… showed no clear difference in short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (low certainty).
Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane Headline outcomes only
RR 5 [0.25, 100.89]1 study · 78 participantsLow

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Treatments for alopecia areata: a network meta‐analysis
2023 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed
How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.